Condition: Acute Spinal Cord Injury (SCI) · Sponsor: Technophage, SA
Technophage identified a promising compound, Eletriptan hydrobromide, that intends to use as a repurposed drug, for the treatment of acute spinal cord injury (SCI) in human subjects. Eletriptan hydrobromide is a well characterized molecule, that has been clinically available for over two decades for the treatment of migraines. It presents a good and manageable safety profile, including for the regimen selected for this trial, and it is generally well tolerated, with minimal side effects. This is an important consideration to have when using repurposed drugs for the treatment of other indications. Technophage believes that the preclinical data collected, in combination with the acceptable safety profile of Eletriptan hydrobromide, support its use as a repurposed drug for the treatment of SCI in humans.
This description comes directly from the study's public registry record.
Sofia Corte-Real · +351 215943993 · scortereal@technophage.pt
Margarida Barreto · +351 215943993 · mbarreto@technophage.pt
Always discuss trial participation with your own doctor first.
| Hospital Universitario Reina Sofia | Córdoba, Spain | Recruiting |
| Hospital Universitario La Paz | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06677229